# Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

> **NCT03838926** · PHASE1 · RECRUITING · sponsor: **Vanda Pharmaceuticals** · enrollment: 42 (estimated)

## Conditions studied

- Relapsed or Refractory Hematologic Malignancies

## Interventions

- **DRUG:** Trichostatin A

## Key facts

- **NCT ID:** NCT03838926
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-09-27
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03838926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03838926, "Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03838926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*